There is a crisis in our industry. R&D spending continues to increase and there is an ever-growing volume of new candidates in clinical phases. However, the rate of successful drugs to market is flat.
Does this reflect your reality?
The pharmaceutical and biotech industries are producing more drug candidates than ever before. The challenge is not to increase the volume of drug candidates, but to improve drug discovery effectiveness — advancing better candidates with greater frequency.
ADMETRx has the solution
Led by company founders Philip Burton and Jay Goodwin, ADMETRx exists to assure that its pharmaceutical and biotech customers achieve their drug discovery goals.
Whether it is to assist in managing capacity issues or to develop sophisticated multi-criteria optimization approaches, ADMETRx can meet your ADME research needs with its high quality data integration.
Our advanced techniques and technologies enable our customers to make informed decisions that save money and dramatically improve the effectiveness of their drug discovery process.
The importance of integration and high quality data has come to the forefront with the examination of the rate of new drug approvals. The following links provide insight relative to how these factors may impact the drug development programs of our clients: